{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 464199526

<!--Monoclonal antibody data-->
| type = mab
| mab_type = mab
| source = zu/o
| target = [[人类表皮生长因子受体II|HER2]]

<!--Clinical data-->
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = NA
| tradename = Perjeta; Omnitarg 
| licence_US        = Pertuzumab
| pregnancy_AU =  
| pregnancy_US = D
| pregnancy_category =  
| legal_AU =  
| legal_CA =  
| legal_UK =  
| legal_US = Rx-only
| legal_status =  
| routes_of_administration = Intravenous

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 380610-27-5
| ATC_prefix = L01
| ATC_suffix =  XC13
| PubChem =  
| ChEMBL = 2007641
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = K16AIQ8CTM
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D05446

<!--Chemical data-->
| chemical_formula =  

| molecular_weight =  
}}
[[Image:Pertuzumab-HER2_complex_1S78.png|thumb]]結構與帕妥珠單抗]]

'''帕妥珠单抗'''（'''Pertuzumab'''，也被称作'''2C4'''，商品名'''Perjeta'''）是一种[[单克隆抗体|单克隆抗体]]。它是第一个被称作“HER二聚化抑制剂”的单克隆抗体。通过结合[[HER2|HER2]]，阻滞了HER2与其它HER受体的[[杂二聚|杂二聚]]，从而减缓了[[肿瘤|肿瘤]]的生长{{R|JCO-deBono}}。帕妥珠单抗在2012年6月8日通过了美国[[FDA|FDA]]的认证，用于治疗HER2阳性的转移性乳腺癌{{R|Genentech}}。帕妥珠单抗由[[Genentech|Genentech]]公司研发，[[罗氏制药|罗氏制药]]于2009年收购了Genentech，帕妥珠单抗现在由罗氏制药掌握。

== 临床试验 ==
{{medical}}
帕妥珠单抗在[[前列腺癌|前列腺癌]]、[[乳腺癌|乳腺癌]]和[[卵巢癌|卵巢癌]]的早期[[临床试验|临床试验]]中获得了一定的成功{{R|release}}。在关键的III期临床试验CLEOPATRA（帕妥珠单抗和[[曲妥珠单抗|曲妥珠单抗]]的临床评价）中，帕妥珠单抗的初始剂量为840mg 静滴，维持剂量为420 mg 静滴，三周一个周期{{R|test}}。同时静脉滴注的帕妥珠单抗和[[多西他赛|多西他赛]]，其[[药代动力学|药代动力学]]不受年龄和药物间相互作用的影响。Gillian Keating在一项回顾性研究中总结了帕妥珠单抗的药代动力学和[[药效学|药效学]]特性{{R|test}}。在随机、双盲的III期CLEOPATRA研究中，帕妥珠单抗联合曲妥珠单抗联合多西他赛与[[安慰剂|安慰剂]]联合曲妥珠单抗联合多西他赛相比，一线治疗HER2阳性转移性乳腺癌，显著地延长了无进展生存期，且心脏毒性没有增加{{R|NEnglJMed}}。
===乳腺癌評估試驗===
目前正有几个试验在评估静脉给药的帕妥珠单抗治疗乳腺癌，这几个试验是：MARIANNE试验（晚期乳腺癌），NEOSPHERE试验（早期乳腺癌），TRYPHAENA试验（HER2阳性II/III乳腺癌）和APHINITY试验（HER2阳性非转移性乳腺癌）{{R|test}}。

== 参考文献 ==
{{reflist|2|refs=

<ref name="JCO-deBono">{{cite journal|last = de Bono|first = Johann S.|title=Open-Label Phase II Study Evaluating the Efficacy and Safety of Two Doses of Pertuzumab in Castrate Chemotherapy-Naive Patients With Hormone-Refractory Prostate Cancer|journal = Journal of Clinical Oncology|volume=25|issue=3|pages=257–262|date=20 January 2007|id=|doi=10.1200/JCO.2006.07.0888|pmid=17235043|last2 = Bellmunt|first2 = J|last3 = Attard|first3 = G|last4 = Droz|first4 = JP|last5 = Miller|first5 = K|last6 = Flechon|first6 = A|last7 = Sternberg|first7 = C|last8 = Parker|first8 = C|last9 = Zugmaier|first9 = G}}</ref>

<ref name="Genentech">{{cite press release|url=http://www.gene.com/gene/news/press-releases/display.do?method=detail&id=14007 |title=FDA Approves Perjeta (Pertuzumab) for People With HER2-Positive Metastatic Breast Cancer |publisher=Genentech |accessdate=2012-06-09}}</ref>

<ref name="release">[http://www.gene.com/gene/news/press-releases/display.do?method=detail&id=8431 Genentech press release] - May 15, 2005</ref>

<ref name="test">Keating GM. Pertuzumab: in the first-line treatment of HER2-positive metastatic breast cancer. ''Drugs 2012 Feb 12; 72 (3): 353-60''.[http://adisonline.com/drugs/pages/articleviewer.aspx?year=2012&issue=72030&article=00005&type=abstract Link text]{{Dead link|date=2018年5月 |bot=InternetArchiveBot |fix-attempted=no }}</ref>

<ref name="NEnglJMed">Baselga J, Cortés J, Kim SB, and the CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. ''N Engl J Med 2012 Jan 12; 366 (2): 109-19''. [http://www.ncbi.nlm.nih.gov/pubmed/22149875 Link text]</ref>
}}

==外部連結==
*[http://www.perjeta.com/ PERJETA™ (pertuzumab) HER2/neu receptor antagonist] {{en icon}}

[[Category:单克隆抗体类|Category:单克隆抗体类]]